The ARIES HeartMate 3 Pump IDE Study

  • End date
    Jul 31, 2023
  • participants needed
  • sponsor
    Abbott Medical Devices
Updated on 7 August 2021
heart failure


Prospective, randomized, double-blinded, placebo-controlled clinical investigation of advanced heart failure patients treated with the HM3 with two different antithrombotic regimens: vitamin K antagonist with aspirin versus vitamin K antagonist with placebo


This clinical investigation is a prospective, randomized, double-blinded, placebo-controlled study of advanced heart failure patients treated with the HM3 with two different antithrombotic regimens: vitamin K antagonist with aspirin versus vitamin K antagonist with placebo.

Condition Heart failure, Heart disease, Congestive Heart Failure, Cardiac Disease, cardiac failure, congestive heart disease
Treatment Placebo Oral Tablet, Aspirin 100mg, LVAD Implant
Clinical Study IdentifierNCT04069156
SponsorAbbott Medical Devices
Last Modified on7 August 2021


Yes No Not Sure

Inclusion Criteria

Subject will receive the HeartMate 3 per standard of care (SOC) in accordance with the approved indications for use in the country of implant
Subject will receive the HeartMate 3 as their first durable VAD
Subject must provide written informed consent prior to any clinical investigation related procedure
In female patients of child bearing capability, subject will not be currently pregnant or breastfeeding and on appropriate contraception

Exclusion Criteria

Post-implant additional temporary or permanent mechanical circulatory support (MCS)
Investigator mandated antiplatelet therapy for other conditions (including mandated presence or absence of antiplatelet agent)
Patients who are nil per os (NPO) post-implant through day 7
Subjects with a known allergy to acetylsalicylic acid (aspirin)
Participation in any other clinical investigation(s) involving an MCS device, or interventional investigation(s) likely to confound study results or affect study outcome
Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note